Send to

Choose Destination
See comment in PubMed Commons below
Oncology. 2012;83(3):117-27. doi: 10.1159/000339539. Epub 2012 Jul 12.

Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.

Author information

Division of Hematology, Oncology, and Blood and Marrow Transplantation, Neuroendocrine Tumor Program, University of Iowa Hospitals and Clinic, Iowa City, Iowa 52242, USA.


Although neuroendocrine tumors (NET) are a relatively rare malignancy, the reported incidence is increasing, and some of the current treatment options are limited in their efficacy. Standard first-line therapy for metastatic small bowel NET includes somatostatin analogs. Although these agents can provide symptom relief and can delay disease progression in many patients, ultimately, new treatments are required for patients with progressive disease. In recent years, there has been considerable interest in developing agents specifically targeted against some of the pathways known to be involved in cancer cell growth, survival and invasion. In 2011, the mammalian target of rapamycin (mTOR) inhibitor everolimus and the tyrosine kinase inhibitor sunitinib were approved for the treatment of pancreatic NET. Clinical trials evaluating novel targeted agents are ongoing, both as single agents and in combination regimens. We review the current clinical status of these potential new treatments and highlight those with particular promise for the management of well-differentiated NET.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland
    Loading ...
    Support Center